JANX
Janux Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$20.24
+2.22%Year over year
Reported trailing growth
- Revenue
- +7162.0%
- EBITDA
- +15.9%
- EBIT
- +0.9%
- EPS
- +8.9%
- Free cash flow
- +10.2%
- Operating cash flow
- +10.4%
Forward estimates
Based on analyst estimates
- Revenue
- -36.6%
- EBITDA
- -40.8%
- EPS
- -41.3%
Three-year CAGR
- Revenue
- +5.1%
- EBITDA
- -66.7%
- EBIT
- -59.5%
- Net income
- -64.7%
- EPS
- -43.0%
- Free cash flow
- -88.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026